Annals of Military and Health Sciences Research

Published by: Kowsar

Dr Allen’s Therapeutic Devices Should be Implemented in the Healthcare System for the Treatment of Chronic Noncancerous Prostate and Kidney Diseases Saving People’s Well-Being and Money

Simon Allen 1 , *
Author Information
1 Fine Treatment, Oxford, United Kingdom
Article information
  • Annals of Military and Health Sciences Research: June 2018, 16 (2); e81033
  • Published Online: August 25, 2018
  • Article Type: Research Article
  • Received: June 19, 2018
  • Revised: August 15, 2018
  • Accepted: August 18, 2018
  • DOI: 10.5812/amh.81033

To Cite: Allen S. Dr Allen’s Therapeutic Devices Should be Implemented in the Healthcare System for the Treatment of Chronic Noncancerous Prostate and Kidney Diseases Saving People’s Well-Being and Money, Ann Mil Health Sci Res. 2018 ; 16(2):e81033. doi: 10.5812/amh.81033.

Abstract
Copyright © 2018, Annals of Military and Health Sciences Research. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnote
References
  • 1. Abdollahi A, Etemadian M, Shoar S, Nozarian Z. Is helicobacter pylori infection a risk factor for prostatitis? a case-control study in a referring tertiary care center. Iran J Pathol. 2016;11(4):323.
  • 2. Chung SD, Huang CC, Lin HC. Chronic prostatitis and depressive disorder: a three year population-based study. J Affect Disord. 2011;134(1-3):404-9. doi: 10.1016/j.jad.2011.05.046. [PubMed: 21665291].
  • 3. Rohrmann S, Katzke V, Kaaks R. Prevalence and Progression of Lower Urinary Tract Symptoms in an Aging Population. Urology. 2016;95:158-63. doi: 10.1016/j.urology.2016.06.021. [PubMed: 27346671].
  • 4. Safarinejad MR. Prevalence of benign prostatic hyperplasia in a population-based study in Iranian men 40 years old or older. Int Urol Nephrol. 2008;40(4):921-31. doi: 10.1007/s11255-008-9338-7. [PubMed: 18246438].
  • 5. Sorokin I, Mamoulakis C, Miyazawa K, Rodgers A, Talati J, Lotan Y. Epidemiology of stone disease across the world. World J Urol. 2017;35(9):1301-20. doi: 10.1007/s00345-017-2008-6. [PubMed: 28213860].
  • 6. Safarinejad MR. Adult urolithiasis in a population-based study in Iran: prevalence, incidence, and associated risk factors. Urol Res. 2007;35(2):73-82. doi: 10.1007/s00240-007-0084-6. [PubMed: 17361397].
  • 7. Franco JV, Turk T, Jung JH, Xiao YT, Iakhno S, Garrote V, Vietto V. Non-pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome. Cochrane Database Syst Rev. 2018;12(5). doi: 10.1002/14651858.CD012551.pub3. [PubMed: 29757454].
  • 8. Voznesensky I, Shaw E, DeLay KJ, Yafi F, Hellstrom WJG. Benign prostatic hyperplasia treatment options and their effects on sexual function. Sex Med Rev. 2017;5(1):87-102. doi: 10.1016/j.sxmr.2016.05.006.
  • 9. Marinkovic SP, Marinkovic CM, Xie D. Spleen injury following left extracorporeal shockwave lithotripsy (ESWL). BMC Urol. 2015;15:4. doi: 10.1186/1471-2490-15-4. [PubMed: 25972225]. [PubMed Central: PMC4429660].
  • 10. Akbulut F, Kucuktopcu O, Ucpinar B, Savun M, Ozgor F, Sonmezay E, et al. A rare complication of extracorporeal shock wave lithotripsy: Intrarenal hematoma mimicking pelvis renalis tumor. Case Rep Urol. 2015;2015:1-4. doi: 10.1155/2015/719618.
  • 11. Krambeck AE, Gettman MT, Rohlinger AL, Lohse CM, Patterson DE, Segura JW. Diabetes mellitus and hypertension associated with shock wave lithotripsy of renal and proximal ureteral stones at 19 years of followup. J Urol. 2006;175(5):1742-7. doi: 10.1016/s0022-5347(05)00989-4.
  • 12. D'Addessi A, Vittori M, Racioppi M, Pinto F, Sacco E, Bassi P. Complications of extracorporeal shock wave lithotripsy for urinary stones: to know and to manage them-a review. ScientificWorldJournal. 2012;2012:619820. doi: 10.1100/2012/619820. [PubMed: 22489195]. [PubMed Central: PMC3317539].
  • 13. Said SHA, Al Kadum Hassan MA, Ali RHG, Aghaways I, Kakamad FH, Mohammad KQ. Percutaneous nephrolithotomy; alarming variables for postoperative bleeding. Arab J Urol. 2017;15(1):24-9. doi: 10.1016/j.aju.2016.12.001.
  • 14. Malik I, Wadhwa R. Percutaneous nephrolithotomy: Current clinical opinions and anesthesiologists perspective. Anesthesiol Res Pract. 2016;2016:1-7. doi: 10.1155/2016/9036872.
  • 15. Herati AS, Moldwin RM. Alternative therapies in the management of chronic prostatitis/chronic pelvic pain syndrome. World J Urol. 2013;31(4):761-6. doi: 10.1007/s00345-013-1097-0. [PubMed: 23740129].
  • 16. Lukacs B, Cornu JN, Aout M, Tessier N, Hodee C, Haab F, et al. Management of lower urinary tract symptoms related to benign prostatic hyperplasia in real-life practice in france: a comprehensive population study. Eur Urol. 2013;64(3):493-501. doi: 10.1016/j.eururo.2013.02.026. [PubMed: 23465519].
  • 17. Moyad MA. Lifestyle changes, CAM, and kidney stones: heart health = kidney health. Complementary and alternative medicine for prostate and urologic health. New York: Springer Science and Business Media; 2014. p. 201-29. doi: 10.1007/978-1-4614-8492-9_8.
  • 18. Herati AS, Shorter B, Srinivasan AK, Tai J, Seideman C, Lesser M, et al. Effects of foods and beverages on the symptoms of chronic prostatitis/chronic pelvic pain syndrome. Urology. 2013;82(6):1376-80. doi: 10.1016/j.urology.2013.07.015. [PubMed: 23978369].
  • 19. Corona G, Vignozzi L, Rastrelli G, Lotti F, Cipriani S, Maggi M. Benign prostatic hyperplasia: a new metabolic disease of the aging male and its correlation with sexual dysfunctions. Int J Endocrinol. 2014;2014. doi: 10.1155/2014/329456. [PubMed: 24688539]. [PubMed Central: PMC3943333].
  • 20. Rendina D, De Filippo G, D'Elia L, Strazzullo P. Metabolic syndrome and nephrolithiasis: a systematic review and meta-analysis of the scientific evidence. J Nephrol. 2014;27(4):371-6. doi: 10.1007/s40620-014-0085-9. [PubMed: 24696310].
  • 21. Allen S, Adjani A. Therapeutic device and method, United States Patent and Trademark Office. 2016. Available from: https://www.google.com/patents/US9408744.
  • 22. Allen S, Aghajanyan IG. Effect of thermobalancing therapy on chronic prostatitis and chronic pelvic pain syndrome. J Clin Urol. 2016;10(4):347-54. doi: 10.1177/2051415816671036.
  • 23. Aghajanyan I, Allen S. Positive response to thermobalancing therapy enabled by therapeutic device in men with non-malignant prostate diseases: BPH and chronic prostatitis. Diseases. 2016;4(4):18. doi: 10.3390/diseases4020018.
  • 24. Allen S, Aghajanyan IG. Benign prostatic hyperplasia treatment with new physiotherapeutic device. Urol j. 2015;12(5):2371-6. [PubMed: 26571324].
  • 25. Allen S, Aghajanyan IG, Schumacher U. Thermobalancing conservative treatment for moderate-to-low-degree lower urinary tract symptoms (LUTS) secondary to prostate enlargement. Cogent Med. 2016;3(1). doi: 10.1080/2331205x.2016.1195067.
  • 26. Allen S. Thermobalancing therapy® should be the first-line treatment for kidney stones and benign prostatic hyperplasia, discussions at the medical conferences. ARC J Urol. 2017;2(3):1-8. doi: 10.20431/2456-060x.0203001.
  • 27. Baldwin AL. Introduction: a brief history of capillaries and some examples of their apparently strange behaviour. Clin Exp Pharmacol Physiol. 2000;27(10):821-5. [PubMed: 11022976].
  • 28. Hansen-Smith FM. Capillary network patterning during angiogenesis. Clin Exp Pharmacol Physiol. 2000;27(10):830-5. [PubMed: 11022978].
  • 29. Allen S. The origin of chronic diseases can be in capillary pathology: an evidence from clinical trials on thermobalancing treatment of prostate reveals. Ach Life Sci. 2016;10(2):197-202. doi: 10.1016/j.als.2016.11.005.
  • 30. Clemens JQ, Markossian T, Calhoun EA. Comparison of economic impact of chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis/painful bladder syndrome. Urology. 2009;73(4):743-6. doi: 10.1016/j.urology.2008.11.007.
  • 31. Speakman M, Kirby R, Doyle S, Ioannou C. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) - focus on the UK. BJU Int. 2015;115(4):508-19. doi: 10.1111/bju.12745.
  • 32. Antonelli JA, Maalouf NM, Pearle MS, Lotan Y. Use of the national health and nutrition examination survey to calculate the impact of obesity and diabetes on cost and prevalence of urolithiasis in 2030. Europ Urol. 2014;66(4):724-9. doi: 10.1016/j.eururo.2014.06.036.
  • 33. Allen S, Aghajanyan IG. New independent thermobalancing treatment with therapeutic device for chronic prostatitis/chronic pelvic pain syndrome. Nephrourol Mon. 2017;9(2). doi: 10.5812/numonthly.44694.
  • 34. Allen S. The vascular factor plays the main role in the cause of pain in men with chronic prostatitis and chronic pelvic pain syndrome: the results of clinical trial on thermobalancing therapy. Diseases. 2017;5(4):25. doi: 10.3390/diseases5040025.
  • 35. Saito M, Tsounapi P, Oikawa R, Shimizu S, Honda M, Sejima T, et al. Prostatic ischemia induces ventral prostatic hyperplasia in the SHR; possible mechanism of development of BPH. Sci Rep. 2014;4(1). doi: 10.1038/srep03822.
  • 36. Thurmond P, Yang JH, Azadzoi KM. LUTS in pelvic ischemia: a new concept in voiding dysfunction. Am J Physiol Renal Physiol. 2016;310(8):F738-43. doi: 10.1152/ajprenal.00333.2015. [PubMed: 26792064].
  • 37. Cohen PG. Abdominal obesity and intra-abdominal pressure: a new paradigm for the pathogenesis of the hypogonadal-obesity-BPH-LUTS connection. Horm Molecul Biol Clin Invest. 2012;11(1):317-20.
  • 38. Allen S. Innovative thermobalancing therapy can help millions of men with enlarged prostate gland to improve the quality of life and well-being throughout the world. World Sci News. 2018;105:51-61.
  • 39. Allen S, Aghajanyan I. Use of thermobalancing therapy in ageing male with benign prostatic hyperplasia with a focus on etiology and pathophysiology. Aging Male. 2017;20(1):28-32. doi: 10.1080/13685538.2016.1247151. [PubMed: 27960590].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments